Key Stats for LMAT Stock
- Price Change for LMAT stock: +24%
- LMAT Share Price as of Feb. 26: $114
- 52-Week High: $115
- LMAT Stock Price Target: $105
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
LeMaitre Vascular (LMAT) stock surged 24.4% to $114 on February 26, 2026, following its fourth-quarter results. According to Reuters, the company reported Q4 sales of $64.5 million, which exceeded the IBES estimate of $62.8 million. The company also posted Q4 EPS of $0.68, up 39% year over year.
Reuters further noted that LeMaitre beat Q4 sales expectations and raised its dividend. The company declared a $0.25 quarterly cash dividend, up from the prior $0.20 level. That dividend increase reinforced confidence in cash flow strength.
The company had announced it would release Q4 and full-year 2025 results on February 25. Investors reacted positively to both the revenue beat and the improved capital return. The stock closed near its 52-week high of $115.33.
This rally also follows steady execution throughout 2025. LeMaitre exceeded sales estimates in Q1, Q2, and now Q4, although Q3 sales were slightly below estimates. Consistent performance helped drive renewed buying interest.
See analysts’ growth forecasts and price targets for LMAT stock (It’s free!) >>>
What the Market Is Telling Us About LMAT Stock
Investors appear to be rewarding profitability and consistency. LeMaitre generated an LTM gross margin of 71.5% and an EBIT margin of 27.2%. Those margins are strong for a medical device manufacturer.
Returns on capital remain healthy. LTM return on equity stands at 15.8%, while return on invested capital is 11.7%. The company also holds a net cash position of $173.5 million, which strengthens its balance sheet.
Growth remains steady rather than explosive. Revenue grew at a 15.6% CAGR over the last three years, and analysts project 10% forward 2-year revenue CAGR. Forward EBITDA CAGR is projected at 14.3%.
However, valuation has expanded alongside performance. The stock trades at 8.6x forward EV/revenue and 27.2x forward EV/EBITDA. On a forward earnings basis, shares trade at 40.3x NTM P/E.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in LeMaitre Vascular, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up LMAT, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track LMAT alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze LeMaitre Vascular stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
